C Diff Treatment

Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).

The prevalence of CDC after hip fracture surgery in elderly patients was 1.43%. CDC after hip fracture in the elderly patients significantly increased the all-cause mortality rate after discharge.

While patients with IBD hospitalized for CDI have poor longitudinal inpatient outcomes, recurrent admissions for CDI may not increase risk of adverse outcomes compared to one-time admission.

Contemporary observations on clostridioides difficile infection in hospitalized children and adolescents

How do we best manage Clostridioides difficle infections in the elderly?

Clostridioides difficile (basonym Clostridium) is a bacterial enteropathogen associated with cases of C. difficile infection that can result in pseudomembranous colitis, rapid fluid loss, and death. For decades following its isolation, C. difficile was thought to be a sol …

UPDATED RECOMMENDATIONS Clostridioides difficile is a spore-forming anaerobic enteropathogen responsible for a wide spectrum of clinical features ranging from mild uncomplicated diarrhoea to severe debilitating disease, toxic megacolon, or even perforation and sometimes death. Risk factors for CDI i …

Healthcare

The prevalence of CDC after hip fracture surgery in elderly patients was 1.43%. CDC after hip fracture in the elderly patients significantly increased the all-cause mortality rate after discharge.

Critically ill patients undergo early impairment of their gut microbiota (GM) due to routine antibiotic therapies and other environmental factors leading to intestinal dysbiosis. The GM establishes connections with the rest of the human body along several axes representing critical inter-organ crosstalks that, once disrupted, play a major role in the pathophysiology of numerous diseases and their complications. Key players in this communication are GM metabolites such as short-chain fatty acids and bile acids, neurotransmitters, hormones, interleukins, and toxins. Intensivists juggle at the crossroad of multiple connections between the intestine and the rest of the body. Harnessing the GM in ICU could improve the management of several challenges, such as infections, traumatic brain injury, heart failure, kidney injury, and liver dysfunction. The study of molecular pathways affected by the GM in different clinical conditions is still at an early stage, and evidence in critically ill patients is lacking. This review aims to describe dysbiosis in critical illness and provide intensivists with a perspective on the potential as adjuvant strategies (e.g., nutrition, probiotics, prebiotics and synbiotics supplementation, adsorbent charcoal, beta-lactamase, and fecal microbiota transplantation) to modulate the GM in ICU patients and attempt to restore eubiosis.

Community-acquired infections (CAI) can affect the duration of care and mortality of patients. Therefore, we aimed to investigate these as well as factors influencing the length of hospital stay in patients with CAI due to enteric pathogens, influenza viruses and multidrug-resistant (MDR) bacteria. …

C. difficile infection isn't without long-term concerns. Why preserving gut microbiome richness is vital in managing C. difficile infection and how to deal with it https://t.co/7n25c460dp #GMFH10Years— GutMicrobiota Health (@GMFHx) December 9, 2022

The 2021 focused update to the Infections Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) guidelines for management of Clostridioides difficile infection (CDI) prioritizes the use of fidaxomicin over vancomycin for the treatment of initial and recurrent …

Elderly patients with CDI and rCDI experienced a significant clinical burden and complications.

Dysbiosis secondary to antibiotic exposure leads to vulnerability to #CDiff with recurrent disease occurring in a significant subset of patients. #Microbiome therapeutics are currently in development that have the potential to help. pic.twitter.com/jJwPascsKQ— MTIG (@MTIG_News) December 8, 2022

Although C. difficile infection has historically been considered a hospital-acquired infection, it is now common in the community settings. Therefore, internal medicine physicians and primary care providers need to be well-versed not only in the diagnosis, but also in the selection of therapy for C, difficile infection. To reduce severe or recurrent C. difficile infection, and C. difficile- associated hospitalizations, physicians must promptly recognize the signs and symptoms of C. difficile infection, identify patients at high risk for recurrence, and select the most treatments while working collaboratively with specialists to improve patient outcomes.

#GMFH2023 has an excellent program in store for you. Don’t miss it!✅ Next-generation probiotics: single strains and consortia✅ Fecal microbiota transplantation✅ Diet and prebiotics✅ Microbiota-derived molecules@esnm_eu @AmerGastroAssn https://t.co/5u0d4X8K5r— GutMicrobiota Health (@GMFHx) December 8, 2022

Introduction: Clostridioides difficile (C. difficile), is a common cause of nosocomial diarrhea. Antibiotic use is a risk factor for developing C. difficile infection (CDI). Clinical presentatio...

Experts share advice for physicians taking care of patients with C. difficile infection (CDI).

Acute diarrhea is a common and debilitating complication in recipients of an allogeneic hematopoietic stem cell transplantation (HCT). In this prospective, observational, and multi-center study we examined all episodes occurring in the first 6 months of 142 consecutive adult patients who underwent a …

Clostridioides difficile infection (CDI) remains a significant clinical challenge both in the management of severe and severe-complicated disease and the prevention of recurrence. Guidelines released by the Infectious Diseases Society of America and Society for Healthcare Epidemiology of America (ID …

The GI infection is increasingly common but little known

It is important to remember that for donor microbiota to thrive and survive in an entirely new environment is no simple feat, so it the best chance by reducing barriers of engraftment in the recipient’s gut via pre-treatment with antibiotics is a logical step. #fmt #guthealth pic.twitter.com/01CFu4YmfR— Novel Biome (@NovelBiome) November 23, 2022

Can we use existing drugs any better? @bhmullish highlights major strengths and caveats of fidaxomicin and rifamixin in terms of efficacy and side effects@esnm_eu #GMFHCoverage pic.twitter.com/fwY06YFnRc— GutMicrobiota Health (@GMFHx) November 22, 2022

.@bhmullish: Ridinilazole is a new drug with some limitations in C. difficile management such as more recurrence compared to vancomycin. However, ridinilazole is more associated with preservation of gut @esnm_eu #GMFHCoverage pic.twitter.com/nSFLJVCJsC— GutMicrobiota Health (@GMFHx) November 22, 2022

“.@bhmullish also summarizes available approaches for preventing C. difficile infection including probiotics, anti-CDI antibiotics and ribaxamase. @esnm_eu #GMFHCoverage”